{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06007417",
            "orgStudyIdInfo": {
                "id": "GenSci004-301"
            },
            "organization": {
                "fullName": "Changchun GeneScience Pharmaceutical Co., Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency",
            "officialTitle": "The Efficacy and Safety of Once-weekly PEG-somatropin (GenSci004) in Treatment-naive Children With Growth Hormone Deficiency: A Randomized, Open-label, Parallel-group, Active-Controlled, Non-inferiority Phase 3 Study (ELEVATE)",
            "acronym": "ELEVATE",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-investigate-efficacy-and-safety-of-weekly-peg-somatropin-in-treatment-naive-children-with-growth-hormone-deficiency"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-09",
            "studyFirstSubmitQcDate": "2023-08-22",
            "studyFirstPostDateStruct": {
                "date": "2023-08-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Changchun GeneScience Pharmaceutical Co., Ltd.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.",
            "detailedDescription": "The purpose of this Phase 3 study is to evaluate the efficacy, safety, and tolerability of weekly GenSci004 compared to daily Genotropin over 52 weeks in prepubertal treatment-na\u00efve children with growth failure due to GHD."
        },
        "conditionsModule": {
            "conditions": [
                "GHD"
            ],
            "keywords": [
                "GHD",
                "growth hormone deficiency"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 162,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "GenSci004",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GenSci004"
                    ]
                },
                {
                    "label": "Genotropin",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Drug: Genotropin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "GenSci004",
                    "description": "GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)",
                    "armGroupLabels": [
                        "GenSci004"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Genotropin",
                    "description": "Genotropin",
                    "armGroupLabels": [
                        "Genotropin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Annualized Height Velocity (AHV) for GenSci004 and Genotropin groups",
                    "description": "Measured in centimeter per year (cm/year)",
                    "timeFrame": "52 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Annualized Height Velocity (AHV) for GenSci004 and Genotropin groups",
                    "description": "Measured in centimeter per year (cm/year)",
                    "timeFrame": "104 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Prepubertal children with GHD in Tanner Stage 1\n2. Baseline HT at least -2.0 SD below the mean HT for CA and sex (HT SDS \u2264 2.0).\n3. Body mass index (BMI) within \u00b12.0 SD of the mean BMI for BA and sex.\n4. Growth hormone stimulation tests: \u226410 ng/mL\n5. Baseline IGF 1 level of at least 1.0 SD below the mean IGF 1 level standardized for age and sex (IGF 1 SDS \u2264-1.0)\n6. Normal 46 XX karyotype for girls.\n7. Children with multiple hormonal deficiencies must be on stable replacement therapy for other hypothalamo-pituitary axes for at least 3 months\n8. Written, signed informed consent of the parent(s) or legal guardian(s) of the participant and written assent of the participant\n\nExclusion Criteria:\n\n1. BA\u2265CA\n2. Prior exposure to rhGH, long-acting growth hormones, or IGF 1 therapy.\n3. Major medical conditions or presence of contraindication to human growth hormone (hGH) treatment\n4. Participation in any other trial of an investigational agent within 3 months prior to Screening.\n5. Any reason per investigator's discretion",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "3 Years",
            "maximumAge": "12 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Peng Duan",
                    "role": "CONTACT",
                    "phone": "+86-431-85195060",
                    "email": "info@gensci-china.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bradley Miller",
                    "affiliation": "University of Minnesota",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Cook Childrens",
                    "city": "Fort Worth",
                    "state": "Texas",
                    "zip": "76104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maria Gomez",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Paul Thornton, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.72541,
                        "lon": -97.32085
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "T2633",
                    "name": "Growth Hormone Deficiency",
                    "asFound": "Growth Hormone Deficiency",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3125",
                    "name": "Isolated Growth Hormone Deficiency",
                    "asFound": "Growth Hormone Deficiency",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}